Apogem Capital’s Solid Biosciences SLDB Stock Holding History

Apogem Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,650	Closed	-$137K	–	208
2021 Q1	$137K	Buy	+1,650	New	+$183K	0.09%	168

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Apogem Capital's SLDB Position: Q2 2021 in Review

Apogem Capital sold out of Solid Biosciences (SLDB) in Q2 2021, closing a stake of 1,650 shares — an estimated $137K sold.

Apogem Capital first reported a position in SLDB in Q1 2021 and held it in 1 quarter. The position peaked at $137K in Q1 2021. 92 funds tracked by Wall St. Rank hold SLDB as of Q2 2021.

Apogem Capital reported no remaining Solid Biosciences position as of Q2 2021 after selling out during the quarter.
Apogem Capital sold 1,650 Solid Biosciences shares in Q2 2021, an estimated $137K.
Apogem Capital first reported a position in Solid Biosciences in Q1 2021 and held it in 1 quarter.
Apogem Capital's Solid Biosciences position peaked at $137K in Q1 2021.
92 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2021.

Based on Apogem Capital's 13F filing for Q2 2021, filed 16 Aug 2021.